中西医结合治疗心房颤动的研究现状
Current Research Status of Integrated Traditional Chinese and Western Medicine in the Treatment of Atrial Fibrillation
摘要: 心房颤动是临床最常见的持续性心律失常,发病率随年龄增长显著上升,与脑卒中、心力衰竭及死亡风险增加密切相关。西医以抗凝、节律控制、心室率控制及导管消融为核心手段,但长期药物不良反应与术后复发问题仍制约疗效。中医将房颤归属于心悸、怔忡范畴,辨治体系历经《内经》奠基、张仲景立论、后世充实,至现代形成本虚标实的核心病机认识,并衍生出络风内动、火郁发之、从脾胃论治等创新学说。近年来,中西医结合方案在房颤的治疗中的优势逐渐突出,凭借西医规范干预与中医药多靶点调控的协同优势,有效弥补了单纯西医在延缓左房结构重构、降低长期复发率等方面的局限。本文系统梳理房颤的中医理论源流、辨证分型规律、西医机制进展及中西医结合干预证据,指出当前证候标准化缺失、高质量循证不足、机制研究薄弱等瓶颈,提出未来应在标准化、循证化与机制化三维协同推进,以期为推进中西医有机结合与深度协同发展提供借鉴。
Abstract: Atrial fibrillation is the most common sustained arrhythmia in clinical practice. Its incidence rises significantly with age and is closely associated with increased risks of stroke, heart failure, and death. Western medicine takes anticoagulation, rhythm control, ventricular rate control, and catheter ablation as core strategies, but long-term adverse drug reactions and postoperative recurrence still restrict the efficacy. Traditional Chinese Medicine (TCM) classifies atrial fibrillation into the categories of “Xinji” (palpitation) and “Zhengchong” (severe palpitation). The system of syndrome differentiation and treatment was founded in the Inner Canon of the Yellow Emperor (Neijing), established by Zhang Zhongjing, and enriched by later generations. In modern times, it has formed the core pathogenesis understanding of “Ben-Xu-Biao-Shi” (deficiency in the root and excess in the manifestation), and derived innovative theories such as “collateral wind stirring internally” (luo feng nei dong), “fire stagnation needing dispersion” (huo yu fa zhi), and “treatment from the spleen and stomach”. In recent years, the advantages of integrated TCM and Western medicine regimens in the treatment of atrial fibrillation have become increasingly prominent. By virtue of the synergistic advantages of standardized Western medical intervention and multi-target regulation of TCM, they effectively compensate for the limitations of Western medicine alone in delaying left atrial structural remodeling and reducing long-term recurrence rates. This paper systematically reviews the TCM theoretical origins of atrial fibrillation, syndrome differentiation patterns, progress in Western medical mechanisms, and evidence of integrated interventions. It points out current bottlenecks such as the lack of syndrome standardization, insufficient high-quality evidence, and weak mechanistic research. It proposes that future research should advance synergistically in three dimensions: standardization, evidence-based medicine, and mechanistic exploration, in order to provide a reference for promoting the organic combination and deep collaborative development of Chinese and Western medicine.
文章引用:陈鹏, 徐惠梅. 中西医结合治疗心房颤动的研究现状[J]. 中医学, 2026, 15(10): 362-367. https://doi.org/10.12677/tcm.2026.1510566

参考文献

[1] 中华医学会心电生理和起搏分会, 中国医师协会心律学专业委员会. 中国心房颤动管理指南(2025) [J]. 中华心律失常学杂志, 2025, 29(4): 265-338.
[2] 王显. 从风论治冠心病的临床实践与思考[J]. 中医学报, 2025, 40(9): 1809-1816.
[3] 杜宜航, 柴若宁, 段城林, 等. 基于“火郁发之”理论探讨宣郁清热法在房颤治疗中的应用[J]. 中国中医基础医学杂志, 2025, 31(4): 707-709.
[4] 万泳宏, 刘建和. 从“阴火-宗气”不两立探讨心房颤动的中医机理和证治[J]. 云南中医中药杂志, 2025, 46(6): 30-33.
[5] 谭玉培, 李明轩, 刘红旭, 等. 从“肺火痰实”探析阵发性房颤的治疗[J]. 中华中医药杂志, 2024, 39(12): 6508-6511.
[6] 丁宇坤, 李思聪, 王显. 《血证论》辨治心房颤动的思想探讨[J]. 中国中医急症, 2024, 33(12): 2206-2208+2215.
[7] 唐荣辰, 宫丽鸿. 心房颤动的中医药治疗研究进展[J]. 中国中医急症, 2024, 33(4): 739-741+749.
[8] 张惠琴. 对319例非瓣膜性心房颤动的中医证候及电解质、甲状腺功能和血脂情况的分析[D]: [硕士学位论文]. 乌鲁木齐: 新疆医科大学, 2023.
[9] Bunnell, D.J. (2025) Atrial Fibrillation. Physician Assistant Clinics, 10, 287-296.
https://doi.org/10.1016/j.cpha.2024.11.005
[10] 王健, 戴婷, 蒋国军, 等. 骨保护蛋白/核因子-κβ受体活化因子/核因子-κβ受体活化因子配体轴与心脏瓣膜病合并持续性心房颤动患者改良迷宫术后心房颤动复发的关系及其作用机制研究[J]. 实用心脑肺血管病杂志, 2020, 28(10): 32-36.
[11] McDermott, L.L., Bohorquez, J., Zaatari, G., et al. (2023) Atrial ECG Dynamics in Atrial Fibrillation. Journal of the American College of Cardiology, 81, 195.
https://doi.org/10.1016/s0735-1097(23)00639-3
[12] Matsunaga-Lee, Y., Egami, Y., Sugino, A., Kobayashi, N., Abe, M., Nohara, H., et al. (2026) Hemoglobin Levels as a Marker of Arrhythmia Recurrence after Atrial Fibrillation Ablation. Journal of Arrhythmia, 42, e70473.
https://doi.org/10.1002/joa3.70473
[13] Luther, V. and Katritsis, G. (2020) Ablation of Atrial Fibrillation and Atrial Tachycardia. In: Decoding Cardiac Electrophysiology, Springer, 73-86.
https://doi.org/10.1007/978-3-030-28672-9_6
[14] 姜兆磊, 曾千龙, 林政宇, 等. 梅氏微创心房颤动消融术治疗心房颤动合并射血分数降低型心力衰竭或射血分数轻度降低型心力衰竭的效果评价[J]. 中国心血管病研究, 2025, 23(4): 293-297.
[15] Puwatnuttasit, P., Chulalaksananukul, R., Sinphurmsukskul, S. and Satitthummanid, S. (2025) Impact of Atrial Fibrillation on Atrial Function in HFpEF. Journal of the American College of Cardiology, 85, 1707.
https://doi.org/10.1016/s0735-1097(25)02191-6
[16] Ren, M., Yao, Y., Yue, X., Ning, Y. and Yang, Y. (2021) Atrial Cardiomyopathy and Atrial Fibrillation in Cancer. Cardiology Research and Practice, 2021, 1-7.
https://doi.org/10.1155/2021/6685953
[17] Petramala, L., Carnevale, R., Marino, L., D’Ambrosio, L., Bartimoccia, S., D’Amico, E.A., et al. (2026) Thrombaxane-b2 as a Predictor Marker of Atrial Fibrillation. International Journal of Cardiology Cardiovascular Risk and Prevention, 29, 200604.
https://doi.org/10.1016/j.ijcrp.2026.200604
[18] 刘萍, 杜玲玲. 除颤复脉方联合缬沙坦对非瓣膜性阵发性心房颤动患者经胺碘酮复律后窦性心律维持及左心房重构和心功能的影响[J]. 现代中西医结合杂志, 2021, 30(22): 2469-2472.
[19] 史亚绘, 石花. 探讨替米沙坦在心房颤动上游治疗中的临床疗效及对患者心房颤动复发率的影响[J]. 中国临床医生杂志, 2021, 49(11): 1304-1307.